Unlock instant, AI-driven research and patent intelligence for your innovation.

Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof

a technology of mtor and inhibitor, which is applied in the field of medicine for treating or preventing eye conditions, disorders, or diseases, can solve the problems of corneal edema, reduced density, and limited regeneration ability of human corneal endothelial cells, and achieve the effects of preserving and/or growing or promoting the growth of corneal endothelial cells

Inactive Publication Date: 2021-04-29
DOSHISHA CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about using a drug called mTOR inhibitor to treat or prevent diseases of the cornea, including Fuchs' endothelial corneal dystrophy and conditions caused by overproduction of extracellular matrix. The drug can also be used to preserve or promote the growth of corneal endothelial cells. This discovery makes a new treatment option available for these diseases, which can affect vision.

Problems solved by technology

Once damaged, human corneal endothelial cells have a very limited ability to regenerate.
Fuchs' endothelial corneal dystrophy is a disease that causes abnormality in endothelial cells inside the cornea and significantly reduces the density of corneal endothelial cells, resulting in edema of the cornea.
Guttae (Corneal guttae) and hypertrophy of the Descemet's membrane are the cause of photophobia or blurred vision in Fuchs' endothelial corneal dystrophy patients, which significantly compromises the QOL of the patients.
It is understood that there is no effective therapeutic method other than corneal transplant for Fuchs' endothelial corneal dystrophy.
However, there is a shortage in cornea donation in Japan, where the number of patients waiting for corneal transplant is about 2600, whereas the number of corneal transplants performed in Japan is approximately 1700 annually.
Therefore, there is a limit to the development of a therapeutic drug thereof.
Currently, there is no therapeutic drug that is used in clinical practice, so that therapy is reliant on corneal transplant.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
  • Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
  • Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof

Examples

Experimental program
Comparison scheme
Effect test

example 4

on Effect of Rapamycin on Phosphorylation Activity of Smad2 / 3 Induced by TGF-β2

[0207]This Example demonstrated suppression effect of rapamycin, which is a typical example of an mTOR inhibitor, on phosphorylation activity of Smad2 / 3 induced by TGF-β2.

[0208](Materials and Methods)

[0209]The medium was removed from a culture dish in which iFECDs were being cultured, and the cells were supplemented with 1×PBS (−) that was preheated to 37° C., and were washed. This was repeated twice. The cells were supplemented again with 1×PBS (−) and incubated for 3 minutes at 37° C. (5% CO2). After removing the PBS (−), the cells were supplemented with 0.05% Trypsin-EDTA (Nacalai Tesque, 32778-34) and incubated for 5 minutes at 37° C. (5% CO2). The cells were then suspended in a medium, and collected by centrifugation at 1500 rpm for 3 minutes. DMEM (Nacalai Tesque, 08456-36)+10% FBS (Biowest, S1820-500)+1% P / S (Nacalai Tesque, 26252-94) was used as the medium.

[0210]iFECDs were seeded on a 12-well pla...

example 5

on Effect of Rapamycin on Production of Fibronectin Induced by TGF-β2

[0217]This Example demonstrated suppression effect of rapamycin, which is a typical example of an mTOR inhibitor, on the production of fibronectin induced by TGF-β2.

[0218](Materials and Methods)

[0219]The medium was removed from a culture dish in which iFECDs were being cultured, and the cells were supplemented with 1×PBS (−) that was preheated to 37° C., and were washed. This was repeated twice. The cells were supplemented again with 1×PBS (−) and incubated for 3 minutes at 37° C. (5% CO2). After removing the PBS (−), the cells were supplemented with 0.05% Trypsin-EDTA (Nacalai Tesque, 32778-34) and incubated for 5 minutes at 37° C. (5% CO2). The cells were then suspended in a medium, and collected by centrifugation at 1500 rpm for 3 minutes. DMEM (Nacalai Tesque, 08456-36)+10% FBS (Biowest, S1820-500)+1% P / S (Nacalai Tesque, 26252-94) was used as the medium.

[0220]iFECDs were seeded on a 6-well plate at a ratio of ...

example 6

A Suppression Effect on mTOR Expression and Phosphorylation of S6K

[0228]This Example demonstrated the suppression effect of mTOR siRNA, which is another typical example of an mTOR inhibitor, on mTOR expression and phosphorylation of S6K.

[0229](Materials and Methods)

[0230]The medium was removed from a culture dish in which iFECDs were being cultured, and the cells were supplemented with 1×PBS (−) that was preheated to 37° C., and were washed. This was repeated twice. The cells were supplemented again with 1×PBS (−) and incubated for 3 minutes at 37° C. (5% CO2). After removing the PBS (−), the cells were supplemented with 0.05% Trypsin-EDTA (Nacalai Tesque, 32778-34) and incubated for 5 minutes at 37° C. (5% CO2). The cells were then suspended in a medium, and collected by centrifugation at 1500 rpm for 3 minutes. DMEM (Nacalai Tesque, 08456-36)+10% FBS (Biowest, S1820-500)+1% P / S (Nacalai Tesque, 26252-94) was used as the medium.

[0231]iFECDs were seeded on a 12-well plate at a ratio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
transparentaaaaaaaaaa
transparencyaaaaaaaaaa
Login to View More

Abstract

The present invention provides a medicine and a method for preventing or treating ophthalmic symptoms, disorders, or diseases. The present invention provides an mTOR-inhibitor-containing composition for preventing or treating ophthalmic symptoms, disorders, or diseases. In some of the embodiments of the present invention, this composition is capable of treating or preventing corneal endothelial symptoms, disorders, or diseases; in particular, corneal endothelial symptoms, disorders, or diseases that are attributed to overexpression of the transforming growth factor-β (TGF-β) signal and / or extracellular matrix (ECM).

Description

TECHNICAL FIELD[0001]The present invention relates to a medicament for treating or preventing eye conditions, disorders, or diseases, comprising an mTOR (also referred to as mechanistic target of rapamycin mammalian target of rapamycin) inhibitor and application thereof.BACKGROUND ART[0002]Visual information is recognized when light transmitted into the cornea, which is a transparent tissue at the front-most part of an eye ball, reaches the retina and excites nerve cells of the retina, and a generated electrical signal is transmitted through the optic nerve to the visual cortex of the cerebrum. To attain good vision, it is necessary that the cornea is transparent. The transparency of the cornea is retained by maintaining constant water content with pumping and barrier functions of corneal endothelial cells.[0003]Human corneal endothelial cells are present at a density of about 3000 cells per 1 mm2 at birth. Once damaged, human corneal endothelial cells have a very limited ability to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/711A61P27/02A61K31/7105
CPCA61K31/711A61K45/06A61K31/7105A61P27/02A61K31/436A61K31/7088A61K45/00A61P43/00A61K31/713A61K9/0048
Inventor KOIZUMI, NORIKOOKUMURA, NAOKI
Owner DOSHISHA CO LTD